共 8 条
- [1] Thoracic Morbidity and Mortality System in Analysis of Postoperative Complications After Pneumonectomy in NSCLC PatientsJOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2351 - S2351Pikin, O.Ryabov, A.Glushko, V.Kolbanov, K.Amiraliev, A.Barmin, V.Alexandrov, O.
- [2] Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non- small cell lung cancerJOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 166 (04) : 1234 - 1244.e13Li, XiangLi, QiuyuanYang, FujunGao, ErjiLin, LeiLi, YaqiangSong, XiaoDuan, Liang
- [3] Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match studyFRONTIERS IN IMMUNOLOGY, 2024, 15Xie, Shu-HanYang, Li-TaoZhang, HaiTang, Zi-LuLin, Zhi-WeiChen, YiHong, Zhi-NuanXu, Rong-YuLin, Wan-LiKang, Ming-Qiang
- [4] PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational StudyJOURNAL OF CANCER, 2021, 12 (24): : 7390 - 7398Yang, XinJiang, LiliJin, YanLi, PengHou, YingyongYun, JingpingWu, ChunyanSun, WenyongFan, XiangshanKuang, DongWang, WeiyaNi, JinsongMao, AnhuaTang, WenminLiu, ZhenhuaWang, JialiXiao, SuijunLi, YuanLin, Dongmei
- [5] The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study (September, 10.1007/s00262-022-03262-w, 2022)CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (03) : 795 - 795Li, ChongwuWu, JunqiJiang, LongZhang, LeiHuang, JiaTian, YuZhao, YueLiu, XiuchengXia, LangHaoran, E.Gao, PeigenHou, LikunYang, MingleiMa, MinjieSu, ChunxiaZhang, HaoChen, HezhongShe, YunlangXie, DongLuo, QingquanChen, Chang
- [6] A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR MutationsINTEGRATIVE CANCER THERAPIES, 2024, 23Kwag, EunbinKim, Soo-DamShin, Seong-HoonOak, ChulhoPark, So-JungChoi, Jun-YongHoon Yoon, SeongKang, In-CheolJeong, Mi-KyungWoo Lee, HyunBang, Sun-HwiSon, Ji WoongLee, SanghunKim, Seung JoonYoo, Hwa-Seung
- [7] A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutationsMEDICINE, 2020, 99 (49)Song, Si-YeonHa, Su-JeongPark, Ji-HyePark, So-JungShin, Seong HoonOak, ChulhoChoi, Jun-YongYoon, Seong WooKim, Jung-AYoon, Seong HoonSon, Ji WoongKim, Seung JoonYoo, Hwa-Seung
- [8] Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort studyLUNG CANCER, 2024, 194Barghout, Samir H.Zhan, Luna JiaRaptis, StarvroulaAl-Agha, FaisalEsfahanian, NikiPopovacki, AimeeKasymjanova, GoulnarProulx-Rocray, FrancisChan, Sze Wah SamuelRichardson, MatthewBrown, M. CatherinePatel, DevalbenDean, Michelle LianeNavani, VishalMoore, EricaCarvery, LaneYan, ElizabethGoldshtein, DanielCleary-Gosine, JasmineGibson, Amanda J. W.Hubley, LynnBalaratnam, KarmugiNgo, TranGill, AzeeBlack, MorganSacher, AdrianBradbury, Penelope A.Shepherd, Frances A.Leighl, NatashaCheema, ParneetKuruvilla, SaraAgulnik, JasonBanerji, ShantanuJuergens, RosalynBlais, NormandCheung, WinsonWheatley-Price, PaulLiu, GeoffreySnow, Stephanie